Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human induced pluripotent stem cell-derived extracellular vesicles (iEVs) are an investigational cell-free regenerative therapy being developed by Shanghai 6th People's Hospital for the treatment of musculoskeletal disorders, specifically lateral epicondylitis (tennis elbow). These vesicles are harvested from the culture media of human induced pluripotent stem cells (iPSCs) and contain a complex cargo of proteins, lipids, and nucleic acids (such as microRNAs) that mediate paracrine signaling. When injected locally into the affected tendon, iEVs are intended to promote tenocyte proliferation, enhance extracellular matrix synthesis, and suppress local inflammation, thereby facilitating tissue repair and functional recovery without the safety concerns associated with direct stem cell transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human induced pluripotent stem cell-derived extracellular vesicles.